Europe – Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5

EMA’s human medicines committee (CHMP) has recommended authorising an adapted Comirnaty vaccine targeting the Omicron XBB.1.5 subvariant. The vaccine – known as Comirnaty Omicron XBB.1.5...
NHS prepares to fast-track ‘game changing’ cancer drugs that target genetic mutations

UK – NHS world first rollout of cancer jab that cuts treatment time by...

Following the green light from the Medicines and Healthcare products Regulatory Agency (MHRA), the NHS in England will be the first health system in...
Advice for Management of Clinical trials in relation to Coronavirus

UK – Nitrosamines impurities in medicines

The Medicines and Healthcare products Regulatory Agency (MHRA) has assessed the risk of nitrosamine formation or presence during the manufacture of human medicines and...

UK – NICE recommends Amryt’s Filsuvez for rare skin disorder

Around 670 people in England with epidermolysis bullosa will benefit from the treatment The National Institute for Health and Care Excellence (NICE) has recommended Amryt...

UK – NICE gives green light for MSD’s Keytruda

The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study MSD has revealed that the National Institute for Health and...

Europe – EMA review of data on paternal exposure to valproate

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) is reviewing data on the potential risk of neurodevelopmental disorders (NDDs) in children conceived by fathers taking valproate medicines. The review...

Europe – Revocation of authorisation for sickle cell disease medicine Adakveo

On 26 May 2023, EMA’s human medicines committee (CHMP) recommended revoking the marketing authorisation for Adakveo (crizanlizumab), a medicine for preventing painful crises (called vaso-occlusive crises)...

Europe – EMA updates Q&A document on publication of clinical trial data

In December 2018 all Clinical Data Publication (CDP) activities were suspended due to the implementation of the EMA’s business continuity plan (BCP). During the COVID-19...

UK – NICE publishes draft guidance not recommending CSL’s haemophilia B gene therapy

The company has been seeking approval for use of the therapy in adults with severe or moderately severe haemophilia B without a history of...

Europe – Paving the way towards coordinated clinical trials in public health emergencies in...

EMA has published a report from a workshop that collected insights and suggestions for possible EU-level actions to improve the way clinical trials are set...

NOS PROCHAINES FORMATIONS